Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-23-032801
Filing Date
2023-02-10
Accepted
2023-02-10 16:57:52
Documents
2
Group Members
ADJUVANT CAPITAL GP, L.P.ADJUVANT CAPITAL MANAGEMENT, L.L.C.ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND DE, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13G d440609dsc13g.htm SC 13G 84698
2 EX-99.1 d440609dex991.htm EX-99.1 6204
  Complete submission text file 0001193125-23-032801.txt   92596
Mailing Address C/O ADJUVANT CAPITAL, L.P. 501 FIFTH AVENUE, SUITE 1404 NEW YORK NY 10017
Business Address C/O ADJUVANT CAPITAL, L.P. 501 FIFTH AVENUE, SUITE 1404 NEW YORK NY 10017 917-334-0724
Adjuvant Global Health Technology Fund, L.P. (Filed by) CIK: 0001783165 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9
Type: SC 13G

Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Subject) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-93617 | Film No.: 23613093
SIC: 2834 Pharmaceutical Preparations